Literature DB >> 10725783

Secretion of noncomplexed 'Big' (10-18 kD) forms of insulin-like growth factor-II by 12 soft tissue sarcoma cell lines.

M W Elmlinger1, U Rauschnabel, E Koscielniak, K Weber, M B Ranke.   

Abstract

The paraneoplastic production of pro-insulin-like growth factor-II (IGF-II) forms causes tumour hypoglycaemias and presumably also has an effect on tumour cell growth. We investigated the molecular weights of IGF-II forms and their ability to form complexes with IGF binding proteins (IGFBPs) in conditioned culture media (CM) from 12 paediatric soft tissue sarcoma (STS) cell lines and from two healthy fibroblast lines. Untreated CM were separated by size exclusion chromatography using biocompatible HPLC. Subsequently, IGF-II, IGFBP-2 and IGFBP-3 were determined in the HPLC fractions by specific RIAs. In the CM, IGF-II concentrations between 0.5 and 8.6 ng/10(6) cells were measured but no IGF-I was detectable. Parallel to this investigation, a high IGF-II mRNA level averaging 44.4 +/- 29.7% was measured by semi-quantitative RT-PCR. The STS cell lines secreted a higher proportion of big-IGF-II forms reaching 10-18 kD (10-33% of the total IGF-II secreted) compared to the healthy fibroblasts (2.5-5%). At the same time, the proportion of IGF-II bound with IGFBP in complexes of 35- 70 kD and 150 kD was reduced by up to 85% in CM from tumour cells. The tumour cell lines apparently secrete a different spectrum of IGF-II forms than healthy fibroblasts. The reduced ability to form complexes with IGFBP and the higher molecular weight of the IGF-II forms produced by the tumour cells indicate that these forms could in fact be the known tumour-associated pro-IGF-II forms. Due to these characteristics, the big-IGF-II forms probably have an altered biological effect on the tumour cells when compared to IGF-II. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10725783     DOI: 10.1159/000023458

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

1.  Role of pro-IGF-II processing by proprotein convertase 4 in human placental development.

Authors:  Qing Qiu; Ajoy Basak; Majambu Mbikay; Benjamin K Tsang; Andrée Gruslin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

2.  Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer.

Authors:  Sameer A Greenall; John D Bentley; Lesley A Pearce; Judith A Scoble; Lindsay G Sparrow; Nicola A Bartone; Xiaowen Xiao; Robert C Baxter; Leah J Cosgrove; Timothy E Adams
Journal:  J Biol Chem       Date:  2012-11-19       Impact factor: 5.157

3.  Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients.

Authors:  C Matuschek; M Rudoy; M Peiper; P A Gerber; N P Hoff; B A Buhren; B Flehmig; W Budach; W T Knoefel; H Bojar; H B Prisack; G Steinbach; V Shukla; A Schwarz; K Kammers; A Erhardt; A Scherer; E Bölke; M Schauer
Journal:  Eur J Med Res       Date:  2011-10-10       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.